Definium Therapeutics, Inc.
NASDAQ:DFTXBiotechnology
-$0.41 today
- Market cap
- $3.99B
- Beta
- 2.38
- P/E (TTM)
- -11.0
- EPS (TTM)
- -$2.18
Volume 1.91M
Average 2.67M
DFTX Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Definium Therapeutics, Inc.NASDAQ: DFTX
Research & Development · Q3 FY2026 · quarter ended Sep 2026
Research & development grows, but more slowly than its trailing trend
Q3 FY2026 research & development of $46.14M rose 48.9% year over year, behind the +60.3% change in trailing-twelve-month research & development. Sequentially, it fell 5.2% from the prior quarter. Over 3 fiscal years it compounded at +48.2% a year.
Context
- Research & development increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +48.9% toward the trailing-twelve-month pace of +60.3%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 117.67M USD
- Year-over-year change
- +80.2%
- 4-year CAGR
- +35.6%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 117.67M | +80.2% |
| FY2024 | 2024-12-31 | 65.3M | +33.4% |
| FY2023 | 2023-12-31 | 48.96M | +35.4% |
| FY2022 | 2022-12-31 | 36.17M | +4.0% |
| FY2021 | 2021-12-31 | 34.79M | — |
Research & Development vs competitors
How DFTX compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +60.3% is the 3rd highest of 10, against a peer median of +19.0%.
- Over three fiscal years its annual growth of +48.2% compares with a peer median of +24.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $5.27B USD | +80515.8% | -26.7% | — | |
| LTM Sep 2026 | $289.11M USD | +17.6% | +19.9% | — | |
| LTM Jun 2026 | $187.86M USD | -3.5% | +46.8% | 24.2% | |
| LTM Mar 2026 | $171.97M USD | +136.8% | +73.1% | — | |
DFTXDefinium Therapeutics, Inc. | LTM Sep 2026 | $169.81M USD | +60.3% | +48.2% | — |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $162.51M USD | -21.6% | +18.9% | — |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | $107.93M USD | +58.7% | +118.3% | 539.7% |
| LTM Mar 2026 | $55.94M USD | +19.0% | +24.4% | — | |
| LTM Mar 2026 | $43.27M USD | +26.5% | +23.7% | — | |
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | $28.47M USD | — | +131.7% | — |
| FY2025 | A$14.4M AUD | -22.7% | -0.8% | 264.8% | |
| Peer median (excluding DFTX) | — | +19.0% | +24.0% | 264.8% | |
Competitors are the stored peer set for DFTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 3.16M | 527K | 0 |
| Gross Profit | 0 | 0 | (3.16M) | (527K) | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 34.79M | 36.17M | 48.96M | 65.3M | 117.67M |
| Selling, General & Admin | 59.07M | 30.16M | 41.74M | 38.62M | 48.64M |
| Operating Expenses | 93.85M | 66.33M | 90.7M | 103.39M | 166.31M |
| Depreciation & Amortization | 2.62M | 3.18M | 3.16M | 527K | 0 |
| EBITDA | (91.22M) | (52.12M) | (92.57M) | (105.87M) | (178.31M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (93.85M) | (66.33M) | (93.87M) | (103.92M) | (166.31M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 1.5M | 5.58M | 11.56M | 10.96M |
| Interest Expense | 359K | 1.5M | 920K | 2.28M | 5.48M |
| Other Income / Expenses | (339K) | 9.54M | (1.87M) | (4.76M) | (17.48M) |
| Income Before Tax | (94.19M) | (56.8M) | (95.73M) | (108.68M) | (183.79M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | (1.16M) | 0 | 0 | 0 | 0 |
| Net Income | (93.04M) | (56.8M) | (95.73M) | (108.68M) | (183.79M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (3.40) | (1.53) | (2.44) | (1.54) | (2.06) |
| EPS (Diluted) | (3.40) | (1.53) | (2.44) | (0.15) | (2.06) |
| Weighted Avg Shares | 27.38M | 30.86M | 39.16M | 70.46M | 89.33M |
| Weighted Avg Shares (Diluted) | 27.38M | 30.86M | 39.16M | 704.61M | 89.33M |
Definium Therapeutics, Inc.
NASDAQ:DFTX
Intrinsic Alpha fair value
Locked
Current Price
$29.12
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.